On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. went on the Joe Rogan Experience and said something big. He claimed 14 of the 19 peptides on the FDA's restricted Category 2 list would likely move back to Category 1. That got a lot of attention fast.
Since then, things have gotten more specific. On July 23 and 24, 2026, an FDA advisory committee reviewed seven of those peptides for the 503A Bulks List, a separate process that decides what compounding pharmacies can legally prepare. The committee voted to recommend six of the seven.
Below, we break down exactly what happened at that meeting, which peptides got a yes vote, which one didn't, and which peptides Kennedy mentioned that still haven't been reviewed at all.
What RFK Jr. Actually Said
The announcement came during Episode 2461 of the Joe Rogan Experience on February 27, 2026. Kennedy Jr. stated that the FDA is working toward a new action on peptide restrictions and expressed hope that people would regain access to these compounds through ethical suppliers. He also criticized the prior administration's handling of the 2023 restrictions, though his comments did not carry any formal regulatory weight.
One more detail worth mentioning. A few people added to the committee ahead of the July meeting have professional backgrounds connected to the peptide industry. This has been noted by outlets covering the meeting. It doesn't change what the committee recommended, but it's useful context if you're curious about how that recommendation came together.
The distinction matters. Understanding what was actually said, and what it does and does not mean under current FDA rules, is important for anyone operating in or relying on the peptide space. As LumaLex Law clearly explains, political commentary and regulatory action are not the same thing, and acting on speculation instead of confirmed law can create real compliance exposure.
A Quick Look at How Peptide Categories Work
To understand what this reclassification would actually change, it helps to know how the FDA's category system works. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, the FDA evaluates bulk drug substances used in compounding and places them into categories based on safety data, clinical need, and manufacturing considerations. The full framework is outlined in the FDA's official interim policy guidance on 503A bulk drug substances.
Here is a simple breakdown of what each category means for substances nominated before January 7, 2025, which includes the peptides currently under discussion:
- Category 1: Substances that may be used in compounding while under evaluation. Eligible for use by licensed compounding pharmacies under a physician prescription if other requirements are met.
- Category 2: Substances identified as potentially presenting significant safety risks. Generally not eligible for routine compounding under current FDA rules.
It is worth noting that the FDA's 2024 updated guidance ended the Category 1, 2, and 3 classification system for any new substances nominated on or after January 7, 2025. The peptides discussed in this blog were nominated before that date, so the category framework still applies to them directly.
Compounded drugs are not FDA approved medications. They are customized preparations made by licensed compounding pharmacies for specific patient needs based on a physician prescription.
Why These Peptides Were Restricted in the First Place
In September 2023, the FDA designated 17 peptides as Category 2 bulk drug substances, a move that effectively restricted licensed compounding pharmacies from preparing them for patients. The stated rationale centered on three main concerns:
- Immunogenicity and the potential for immune reactions
- Manufacturing impurities and peptide-related impurities from the compounding process
- Lack of large-scale human clinical trial data to support safe use
The restrictions effectively ended the ability of licensed compounding pharmacies to prepare these compounds for patients. Demand did not disappear, however. It shifted to unregulated gray market vendors selling peptides labeled as "for research use only," with no pharmaceutical oversight, no quality control, and no physician oversight. As Frier Levitt FDA Law noted, this outcome became a central argument for reconsidering the original restrictions.
Which Peptides Actually Got a Committee Vote, and Which Are Still Just Talk
Let's split this into two groups, because that's the clearest way to think about it.
Peptides with an actual committee recommendation.
These seven went in front of the FDA's advisory committee on July 23 and 24, 2026:
- BPC-157: studied for gut healing and tissue repair. Recommended for the Bulks List.
- KPV: studied for gut health and inflammation. Recommended.
- TB-500: studied for wound healing. Recommended
- MOTS-c: studied for metabolism and insulin sensitivity. Recommended.
- Semax: studied for cognitive function. Recommended.
- Epitalon: studied for longevity and hormone balance. Recommended.
- DSIP, also called Emideltide: studied for sleep and opioid withdrawal. Not recommended. The committee voted this one down.
Six out of seven got a yes vote. Keep in mind, this is just a recommendation. The FDA hasn't made it official yet. Want the full vote count for each one? Check our breakdown of the July 2026 FDA peptide vote.
Peptides Kennedy mentioned, but that never went in front of the committee
These weren't part of the July meeting at all:
- Thymosin Alpha 1: used for immune support.
- AOD-9604: studied for fat metabolism.
- GHK-Cu (injectable): a copper peptide for tissue repair.
- CJC-1295: a growth hormone peptide.
- Ipamorelin: another growth hormone peptide.
- Thymosin Beta 4 fragment (LKKTETQ): studied for tissue repair.
- Selank: studied for cognitive function.
- Kisspeptin-10: studied for hormone balance.
Nothing official has happened with these yet. They're in the same spot they were in back in February.
A few peptides are expected to stay restricted no matter what: Melanotan II, GHRP-2, LL-37, and PEG-MGF. These weren't part of the July review either, and they carry more specific safety flags.
What Reclassification Does and Does Not Mean
This is the part that is getting lost in a lot of the conversation around Kennedy Jr.'s announcement. Category 1 reclassification is not the same as FDA approval, and the distinction is important.
Here is what reclassification to Category 1 would mean:
- Licensed compounding pharmacies can legally prepare these peptides again
- Access requires a valid physician prescription
- Compounding must meet USP 797 and 795 standards for sterility and quality control
- These remain compounded drugs, not FDA approved medications
Here is what it does not mean:
- The peptides are not FDA approved drugs
- Over-the-counter access is not anticipated
- Gray market peptides sold as research chemicals remain unregulated and carry serious safety risks
- The formal FDA publication has not yet been released
For anyone considering peptide therapies, sourcing from licensed providers and working under physician oversight remains the only responsible path forward.
The 503A and 503B Compounding Framework
Much of the legal complexity around peptide restrictions comes down to how compounding pharmacies operate under federal law. Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act govern two different types of compounding:
- 503A covers traditional pharmacy compounding for individual patient prescriptions
- 503B covers outsourcing facilities that produce compounded drugs at larger scale
Peptides that appear on the Category 1 bulk substances list can be compounded under these frameworks, subject to specific conditions. Inclusion on the list is not permanent and depends on ongoing FDA review of safety data, clinical need, and manufacturing considerations. State regulations also apply alongside federal requirements, and compounding pharmacists must comply with both.
If peptides are formally returned to Category 1, pharmacies operating under 503A would be able to prepare them again for patient-specific use with a valid physician prescription.
Why This Matters for Drug Development and FDA Approval
The broader regulatory question behind this reclassification goes beyond access. It touches on the economics of drug development and what happens when compounded versions of a compound are widely available.
When patients can access a peptide through compounding pharmacies at a fraction of the cost, pharmaceutical companies have less incentive to invest in the full FDA approval process, which requires clinical trials, manufacturing validation, and extensive regulatory submission and review. Reclassification to Category 2 was partly intended to rebalance that equation.
Returning these peptides to Category 1 does not resolve that tension. Most peptides remain unapproved treatments under federal law, and the path to full FDA approved drug status remains a long and expensive one. The difference is that regulated access through licensed compounding pharmacies is now being recognized as safer than the gray market alternative it inadvertently created.
Safety Concerns That Still Apply
Here's some context worth knowing. Going into the July meeting, the human research on these peptides was still fairly limited. For BPC-157, most of the available human data came from a small study using an enema rather than an injection. For TB-500, reviewers noted they hadn't yet come across published human studies.
There are also some manufacturing details to be aware of. A few of these peptides don't dissolve in water as easily as others, which can affect dose consistency from one injection to the next. Reviewers also mentioned the potential for immune response if the peptide molecules clump together during preparation.
The committee's recommendation was based on weighing these factors against the risks of the unregulated market, not on new clinical data resolving them. That's part of why working with a licensed provider matters, someone who can help interpret what the current research does and doesn't show.
What This Means for Compounding Pharmacies and Clinicians
For compounding pharmacies, the potential return of these peptides to legal compounding status represents a meaningful expansion of what they can prepare. But compliance does not automatically follow from reclassification. Pharmacies will need to verify the formal FDA publication before resuming compounding, confirm that their processes meet current quality control and documentation standards, and remain compliant with both federal and applicable state regulations.
For clinicians, the guidance from regulatory and legal experts is consistent: prescribing authority does not override compounding restrictions. Until the FDA formally publishes an updated bulk substances list, compounding these peptides still carries regulatory risk under the current legal framework. Working with pharmacy partners who are actively monitoring guidance documents and FDA actions is a practical step toward staying compliant.
A Signal, Not a Final Decision
Kennedy Jr.'s comments represent a clear signal of where the current administration wants to take peptide regulation. They reflect a broader view within the Department of Health and Human Services that the 2023 restrictions went too far and that regulated access through licensed compounding pharmacies is preferable to pushing patients toward unregulated markets.
A committee recommendation isn't the same as a final rule. The FDA has said a short-term update could come within a few weeks, likely addressing whether pharmacies get some flexibility while the bigger review continues. Making the change official and permanent on the Bulks List is a longer process, and attorneys who track FDA rulemaking estimate that could take up to a year.
So the picture is clearer than it was back in February, even though the final details are still being worked out.
Where the Peptide Industry Goes from Here
The 2023 restrictions created a market that arguably worked against the safety goals they were designed to achieve. The expected return of 14 peptides to legal compounding status is a step toward correcting that. It restores a regulated pathway, brings volume back to licensed providers, and gives patients access to physician-supervised care rather than gray market sourcing.
What it does not do is settle every question around peptide restrictions long term. Safety data for many peptides remains limited. Clinical trials for most have not reached the scale required for full FDA approval. The boundary between compounding flexibility and formal drug development is still being drawn.
For brands, clinicians, and patients operating in this space, staying informed as the formal FDA guidance develops is the most practical step forward. Watch for the official updated bulk substances list, work with licensed providers, and treat Kennedy Jr.'s announcement as the opening of a door, not the final word.
